Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Niraparib in the PRIMA Trial
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
Efficacy | ZEJULA (niraparib) for HCPs
First-line niraparib is associated with improvement in QA-PFS and QA-TWiST
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count : results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer | Targeted Oncology
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
Efficacy | ZEJULA (niraparib) for HCPs
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Efficacy of niraparib in the PRIMA trial | Download Scientific Diagram
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Efficacy | ZEJULA (niraparib) for HCPs
Stephen V Liu, MD on X: "#ESMO19 Practice changing study presented by Antonio Gonzalez Martin. PRIMA study of niraparib in patients with ovarian cancer responding to 1L platinum based chemo. Primary endpoint
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets - The ASCO Post
